- Home
- NZF vs LIVN Comparison
NZF vs LIVN Comparison
Compare NZF & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NZF
- LIVN
- Stock Information
- Founded
- NZF 2001
- LIVN 1987
- Country
- NZF United States
- LIVN United Kingdom
- Employees
- NZF N/A
- LIVN N/A
- Industry
- NZF Finance Companies
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NZF Finance
- LIVN Health Care
- Exchange
- NZF Nasdaq
- LIVN Nasdaq
- Market Cap
- NZF 2.3B
- LIVN 2.1B
- IPO Year
- NZF N/A
- LIVN 1993
- Fundamental
- Price
- NZF $12.33
- LIVN $54.53
- Analyst Decision
- NZF
- LIVN Strong Buy
- Analyst Count
- NZF 0
- LIVN 7
- Target Price
- NZF N/A
- LIVN $59.71
- AVG Volume (30 Days)
- NZF 496.8K
- LIVN 583.7K
- Earning Date
- NZF 01-01-0001
- LIVN 10-29-2025
- Dividend Yield
- NZF 4.67%
- LIVN N/A
- EPS Growth
- NZF N/A
- LIVN N/A
- EPS
- NZF N/A
- LIVN N/A
- Revenue
- NZF N/A
- LIVN $1,309,329,000.00
- Revenue This Year
- NZF N/A
- LIVN $11.29
- Revenue Next Year
- NZF N/A
- LIVN $6.59
- P/E Ratio
- NZF N/A
- LIVN N/A
- Revenue Growth
- NZF N/A
- LIVN 8.23
- 52 Week Low
- NZF $9.82
- LIVN $32.48
- 52 Week High
- NZF $12.29
- LIVN $58.91
- Technical
- Relative Strength Index (RSI)
- NZF 63.15
- LIVN 50.60
- Support Level
- NZF $11.88
- LIVN $56.42
- Resistance Level
- NZF $12.52
- LIVN $57.53
- Average True Range (ATR)
- NZF 0.11
- LIVN 1.35
- MACD
- NZF 0.02
- LIVN -0.70
- Stochastic Oscillator
- NZF 70.00
- LIVN 10.25
About NZF Nuveen Municipal Credit Income Fund
Nuveen Municipal Credit Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and to enhance portfolio value relative to the municipal bond market by investing in an actively managed portfolio of tax-exempt municipal securities.
About LIVN LivaNova PLC
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.